Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Purchases $999,306.82 in Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Richard A. Md Miller bought 577,634 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was acquired at an average price of $1.73 per share, with a total value of $999,306.82. Following the completion of the purchase, the chief executive officer now directly owns 577,634 shares of the company’s stock, valued at approximately $999,306.82. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Corvus Pharmaceuticals Stock Up 3.6 %

CRVS opened at $2.03 on Friday. The company has a 50 day moving average of $1.77 and a two-hundred day moving average of $1.79. Corvus Pharmaceuticals, Inc. has a 52-week low of $1.05 and a 52-week high of $4.19. The company has a market cap of $99.55 million, a P/E ratio of -3.90 and a beta of 1.05.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Tuesday, March 19th. The company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). Research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A hedge fund recently raised its stake in Corvus Pharmaceuticals stock. Towerview LLC grew its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 67.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 342,478 shares of the company’s stock after purchasing an additional 137,478 shares during the period. Corvus Pharmaceuticals accounts for 0.3% of Towerview LLC’s portfolio, making the stock its 18th biggest position. Towerview LLC owned approximately 0.70% of Corvus Pharmaceuticals worth $500,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

CRVS has been the topic of several recent analyst reports. Oppenheimer increased their price objective on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Finally, Mizuho reissued a “neutral” rating and set a $3.50 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.